How do venture capitalists evaluate early stage life science companies to decide where to place their bets? Learn how high-profile VCs evaluate startups, and what data sets are most important for early stage companies looking to attract capital. Featuring a panel of life science venture investors and moderated by a senior correspondent at Endpoints, this panel will help you learn what to prioritize and present to show off your strongest science, preclinical data, IP and management team, and how you’ll address your potential patient market. Gain a better understanding of how VCs and investment committees assess risk - and how your startup can put its best foot forward when seeking funding.